Clinical Trials | December 31, 2025
GenSight Biologics gets early access nod for candidate gene therapy in Israel
Applications include detailed scientific rationale and supporting clinical evidence
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
The agreement to sell B Medical Systems marks a major step forward in simplifying the portfolio to prioritize our core capabilities with the highest strategic impact
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
The plant is expected to enhance regional supply capabilities
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
The study met its primary endpoint with flying colors
Subscribe To Our Newsletter & Stay Updated
